586 related articles for article (PubMed ID: 36324151)
21. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
[TBL] [Abstract][Full Text] [Related]
22. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
23. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
24. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
Luo Y; Tan L; Therriault J; Zhang H; Gao Y;
Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229
[TBL] [Abstract][Full Text] [Related]
25. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
26. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
27. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
28. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences.
Xu C; Xiao D; Su BB; Saveron JM; Gamez D; Navia RO; Wang N; Roy U; Adjeroh DA; Wang K;
Neurol Sci; 2024 Mar; 45(3):1041-1050. PubMed ID: 37759100
[TBL] [Abstract][Full Text] [Related]
29. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias.
Cicognola C; Hansson O; Scheltens P; Kvartsberg H; Zetterberg H; Teunissen CE; Blennow K
Alzheimers Res Ther; 2021 Feb; 13(1):38. PubMed ID: 33557920
[TBL] [Abstract][Full Text] [Related]
31. Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease.
Ghahremani M; Wang M; Chen HY; Zetterberg H; Smith E; Ismail Z;
Neurology; 2023 Feb; 100(7):e683-e693. PubMed ID: 36323521
[TBL] [Abstract][Full Text] [Related]
32. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
Drake JD; Chambers AB; Ott BR; Daiello LA;
J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
[TBL] [Abstract][Full Text] [Related]
33. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
[TBL] [Abstract][Full Text] [Related]
34. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
35. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
36. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
37. Association of CSF Aβ
Cullen N; Janelidze S; Palmqvist S; Stomrud E; Mattsson-Carlgren N; Hansson O;
Neurology; 2022 Mar; 98(9):e958-e967. PubMed ID: 34937781
[TBL] [Abstract][Full Text] [Related]
38. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
[TBL] [Abstract][Full Text] [Related]
39. Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses.
Rouch L; Virecoulon Giudici K; Cantet C; Guyonnet S; Delrieu J; Legrand P; Catheline D; Andrieu S; Weiner M; de Souto Barreto P; Vellas B;
Am J Clin Nutr; 2022 Dec; 116(6):1492-1506. PubMed ID: 36253968
[TBL] [Abstract][Full Text] [Related]
40. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.
Sagare AP; Deane R; Zetterberg H; Wallin A; Blennow K; Zlokovic BV
J Alzheimers Dis; 2011; 24(1):25-34. PubMed ID: 21157031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]